Earlier this year, Ichnos Glenmark Innovation (IGI) and AbbVie had announced an exclusive Global Licensing Agreement for ISB 2001, which is a Trispecific Antibody for Multiple Myeloma. Under the terms of the first-of-its-kind agreement for an Indian biotech player, AbbVie has exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China.